Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:21:53.023Z.
Calculation as of: 2026-10-06T16:21:53.023Z.
Quote observation: 2026-10-06T16:20:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0cade57d6bc8828dc71ac364ddc44a4328d7c948fb2699a56d4eea8e3f6e5b7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.35B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Price/FCF Ratio
54.58
TTM Avg
40.41
3Y Avg
45.21
5Y Avg
44.82
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.32B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.36B | N/A | 2.59 | 2.60 | 2.60 |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.23B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 54.58 | 40.41 | 45.21 | 44.82 |
| Omada Health (OMDA)vs › | $1.22B | 60.97 | 62.80 | 62.80 | 62.80 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 24.54 | 2775.83 | 1287.19 | 1287.19 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
